ESMO-Magnitude of Clinical Benefit Scale

MCBS Banner 1180x184

The ESMO-MCBS is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies at the time of approval.

The below filter has been created to provide a centralised location of cancer medicines that have been scored using ESMO-MCBS v1.1 and published by ESMO.

ESMO-MCBS grading

Curative setting grading  - A (major benefit), B (important benefit), C (minor benefit):

  • Form 1   - For new approaches to adjuvant therapy or new potentially curative therapies

Non-curative setting grading - 5 and 4 (substantial benefit), 3 (moderate benefit), 2 and 1 (negligible benefit):

  • Form 2a   - For therapies that are not likely to be curative with primary endpoint of OS 
  • Form 2b   - For therapies that are not likely to be curative with primary endpoint PFS 
  • Form 2c   - For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies 
  • Form 3     - For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR 

For full information please click here

The ESMO-MCBS Score Card

The ESMO-MCBS Score Card allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Score card
Trastuzumab Chemotherapy Adjuvant or neo-adjuvant HER2 positive tumours Breast Cancer Breast Cancer HER2+ Early
A
Epirubicin, 5FU, Cisplatin Surgery Peri-operative Gastrointestinal Cancers Oesophageal or Gastric Cancer Early
A
5FU, Cisplatin Surgery Peri-operative Gastrointestinal Cancers Oesophageal or Gastric Cancer Early
A
Ipilimumab Placebo Adjuvant stage III melanoma Skin Cancers Melanoma Early
A
Ipilimumab Dacarbazine Dacarbazine + placebo 1st line metastatic Skin Cancers Melanoma Metastatic
4
Dinutuximab Cis retinoic acid+GMCSF+IL2 Cis retinoic acid <32 years old with high-risk neuroblastoma after remission and stem cell transplatation Central Nervous System Malignancies Neuro-oncology cancer Neuroblastoma Early
A
FLOT (docetaxel, oxaliplatin, fluorouracil and leucovorin) Fluorouracil or capecitabine plus cisplatin and epirubicin Resectable gastric or gastro-oesophageal junction adenocarcinoma with clinical stage cT2 or higher, nodal positive (cN+) disease or both Gastrointestinal Cancers Gastric and gastro-oesophageal junction cancers Early
A
Gemcitabine Capecitabine Gemcitabine Resected pancreatic ductal adenocarcinoma Gastrointestinal Cancers Pancreatic cancer Early
A
mFOLFIRINOX Gemcitabine Resected pancreatic ductal adenocarcinoma Gastrointestinal Cancers Pancreatic cancer Early
A
Neratinib Placebo After trastuzumab based adjuvant therapy in early HER2+ Breast Cancer Breast Cancer HER2+ Early
A

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings